vs

Side-by-side financial comparison of Granite Ridge Resources, Inc. (GRNT) and MESA LABORATORIES INC (MLAB). Click either name above to swap in a different company.

Granite Ridge Resources, Inc. is the larger business by last-quarter revenue ($105.5M vs $65.1M, roughly 1.6× MESA LABORATORIES INC). On growth, MESA LABORATORIES INC posted the faster year-over-year revenue change (3.6% vs -0.8%). Over the past eight quarters, Granite Ridge Resources, Inc.'s revenue compounded faster (8.9% CAGR vs 5.1%).

Granite Ridge Resources, Inc. is an independent upstream energy company focused on the exploration, development, and production of oil, natural gas, and natural gas liquids. It operates low-cost, high-yield onshore hydrocarbon assets across key U.S. basins, primarily serving North American energy markets.

Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.

GRNT vs MLAB — Head-to-Head

Bigger by revenue
GRNT
GRNT
1.6× larger
GRNT
$105.5M
$65.1M
MLAB
Growing faster (revenue YoY)
MLAB
MLAB
+4.4% gap
MLAB
3.6%
-0.8%
GRNT
Faster 2-yr revenue CAGR
GRNT
GRNT
Annualised
GRNT
8.9%
5.1%
MLAB

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
GRNT
GRNT
MLAB
MLAB
Revenue
$105.5M
$65.1M
Net Profit
$3.6M
Gross Margin
64.2%
Operating Margin
-34.5%
12.2%
Net Margin
5.6%
Revenue YoY
-0.8%
3.6%
Net Profit YoY
316.6%
EPS (diluted)
$-0.19
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GRNT
GRNT
MLAB
MLAB
Q4 25
$105.5M
$65.1M
Q3 25
$112.7M
$60.7M
Q2 25
$109.2M
$59.5M
Q1 25
$122.9M
$62.1M
Q4 24
$106.3M
$62.8M
Q3 24
$94.1M
$57.8M
Q2 24
$90.7M
$58.2M
Q1 24
$89.0M
$58.9M
Net Profit
GRNT
GRNT
MLAB
MLAB
Q4 25
$3.6M
Q3 25
$14.5M
$2.5M
Q2 25
$25.1M
$4.7M
Q1 25
$9.8M
$-7.1M
Q4 24
$-1.7M
Q3 24
$9.1M
$3.4M
Q2 24
$5.1M
$3.4M
Q1 24
$16.2M
$-254.6M
Gross Margin
GRNT
GRNT
MLAB
MLAB
Q4 25
64.2%
Q3 25
61.5%
Q2 25
62.0%
Q1 25
61.8%
Q4 24
63.3%
Q3 24
61.3%
Q2 24
64.0%
Q1 24
62.1%
Operating Margin
GRNT
GRNT
MLAB
MLAB
Q4 25
-34.5%
12.2%
Q3 25
17.4%
7.8%
Q2 25
19.0%
5.1%
Q1 25
34.6%
2.4%
Q4 24
-6.5%
9.2%
Q3 24
26.2%
6.1%
Q2 24
24.1%
9.6%
Q1 24
22.0%
-460.6%
Net Margin
GRNT
GRNT
MLAB
MLAB
Q4 25
5.6%
Q3 25
12.9%
4.1%
Q2 25
23.0%
8.0%
Q1 25
8.0%
-11.4%
Q4 24
-2.7%
Q3 24
9.6%
5.9%
Q2 24
5.6%
5.8%
Q1 24
18.2%
-432.2%
EPS (diluted)
GRNT
GRNT
MLAB
MLAB
Q4 25
$-0.19
$0.65
Q3 25
$0.11
$0.45
Q2 25
$0.19
$0.85
Q1 25
$0.07
$-1.30
Q4 24
$-0.09
$-0.31
Q3 24
$0.07
$0.63
Q2 24
$0.04
$0.62
Q1 24
$0.12
$-47.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GRNT
GRNT
MLAB
MLAB
Cash + ST InvestmentsLiquidity on hand
$29.0M
Total DebtLower is stronger
$367.8M
$68.4M
Stockholders' EquityBook value
$605.8M
$186.7M
Total Assets
$1.2B
$434.8M
Debt / EquityLower = less leverage
0.61×
0.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GRNT
GRNT
MLAB
MLAB
Q4 25
$29.0M
Q3 25
$20.4M
Q2 25
$21.3M
Q1 25
$27.3M
Q4 24
$27.3M
Q3 24
$24.3M
Q2 24
$28.5M
Q1 24
$28.2M
Total Debt
GRNT
GRNT
MLAB
MLAB
Q4 25
$367.8M
$68.4M
Q3 25
$300.0M
$69.4M
Q2 25
$275.0M
$70.3M
Q1 25
$250.0M
$71.3M
Q4 24
$205.0M
$72.2M
Q3 24
$73.1M
Q2 24
$74.1M
Q1 24
$137.5M
Stockholders' Equity
GRNT
GRNT
MLAB
MLAB
Q4 25
$605.8M
$186.7M
Q3 25
$643.9M
$178.5M
Q2 25
$642.5M
$172.5M
Q1 25
$631.4M
$159.8M
Q4 24
$635.4M
$155.2M
Q3 24
$660.6M
$161.5M
Q2 24
$665.3M
$150.7M
Q1 24
$674.0M
$145.4M
Total Assets
GRNT
GRNT
MLAB
MLAB
Q4 25
$1.2B
$434.8M
Q3 25
$1.1B
$430.4M
Q2 25
$1.1B
$435.7M
Q1 25
$1.1B
$433.3M
Q4 24
$1.0B
$433.3M
Q3 24
$1.0B
$454.1M
Q2 24
$990.5M
$440.4M
Q1 24
$966.7M
$446.8M
Debt / Equity
GRNT
GRNT
MLAB
MLAB
Q4 25
0.61×
0.37×
Q3 25
0.47×
0.39×
Q2 25
0.43×
0.41×
Q1 25
0.40×
0.45×
Q4 24
0.32×
0.47×
Q3 24
0.45×
Q2 24
0.49×
Q1 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GRNT
GRNT
MLAB
MLAB
Operating Cash FlowLast quarter
$64.5M
$18.8M
Free Cash FlowOCF − Capex
$18.0M
FCF MarginFCF / Revenue
27.7%
Capex IntensityCapex / Revenue
1.1%
Cash ConversionOCF / Net Profit
5.17×
TTM Free Cash FlowTrailing 4 quarters
$37.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GRNT
GRNT
MLAB
MLAB
Q4 25
$64.5M
$18.8M
Q3 25
$77.8M
$8.2M
Q2 25
$78.0M
$1.9M
Q1 25
$76.1M
$12.7M
Q4 24
$68.2M
$18.1M
Q3 24
$74.7M
$5.3M
Q2 24
$64.2M
$10.7M
Q1 24
$68.7M
$12.9M
Free Cash Flow
GRNT
GRNT
MLAB
MLAB
Q4 25
$18.0M
Q3 25
$7.1M
Q2 25
$884.0K
Q1 25
$11.9M
Q4 24
$17.3M
Q3 24
$3.5M
Q2 24
$9.9M
Q1 24
$12.3M
FCF Margin
GRNT
GRNT
MLAB
MLAB
Q4 25
27.7%
Q3 25
11.7%
Q2 25
1.5%
Q1 25
19.2%
Q4 24
27.6%
Q3 24
6.0%
Q2 24
16.9%
Q1 24
21.0%
Capex Intensity
GRNT
GRNT
MLAB
MLAB
Q4 25
1.1%
Q3 25
1.8%
Q2 25
1.7%
Q1 25
1.2%
Q4 24
1.3%
Q3 24
3.1%
Q2 24
1.5%
Q1 24
0.9%
Cash Conversion
GRNT
GRNT
MLAB
MLAB
Q4 25
5.17×
Q3 25
5.36×
3.32×
Q2 25
3.11×
0.40×
Q1 25
7.75×
Q4 24
Q3 24
8.25×
1.54×
Q2 24
12.58×
3.17×
Q1 24
4.23×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GRNT
GRNT

Oil And Gas Service$87.6M83%
Natural Gas Storage$17.9M17%

MLAB
MLAB

Sterilization And Disinfection Control$24.9M38%
Biopharmaceutical Development$14.4M22%
Other$14.1M22%
Clinical Genomics$11.8M18%

Related Comparisons